CEO SUMMARY: With patience and persistence, Digene, Inc. is developing the effectiveness of its DNA-based HPV assay. Publication of recently-completed clinical trials provides evidence that Digene’s Hybrid Capture II ® HPV test, with further improvement, might become a relevant tool in the diagnostic pathway for cervical cancer. It’s another new technology with the potential to […]
Pap Technology Wars Expected to Intensify
Digene’s blood-based HPV assay produces more favorable data with latest trial results
- By Robert Michel
- > From the Volume VII No. 5 - March 27, 2000 Issue
- Tags: blood tests, cap, clinical lab, Clinical Laboratory, clinical laboratory industry, clinical trials, commercial laboratories, cpt, cpt code, dark report, hie, impac, lab executive, laboratories, laboratory industry, laboratory medicine, managed care, Medicare, pathologists, private payer, smear test, the clinical laboratory, the dark report, tripath imaging
